Should You Scoop Up Bristol Myers Squibb Shares?
Given the extreme volatility the stock market has experienced in the devastating wake of COVID-19, many investors have been setting their sights on dividend stocks as a means of mitigating their long-term losses from the coronavirus crash. Bristol Myers Squibb (NYSE: BMY) has historically been a top choice for dividend investors with its excellent use of cash flow, consistent revenue growth, and substantial annual dividend increases. In fact, in the past five years alone, Bristol Myers Squibb has boosted its dividend four times with a median rise of 2.4% each year.
In the current COVID-19 buying climate, very few stocks are proving to be totally recession-proof. That said, those with a long-term buying strategy in mind should be seeking investment opportunities in stocks that have shown healthy signs of recovery over the past month and have a diverse-enough product portfolio to ride the shock waves that are likely still ahead. It would appear that Bristol Myers is such a stock.
Keep reading to learn why you may want to consider incorporating Bristol Myers into your buying strategy.
Source Fool.com
